Composition including lactobacillus kunkeei nchbl-003 strain or inactivated cells thereof as active ingredient for treatment, prevention, or alleviation of respiratory or inflammatory diseases

The Lactobacillus kunkei NCHBL-003 strain or its dead cells are used in a composition to address the limitations of current treatments for acute lung injury and acute respiratory distress syndrome by inhibiting inflammatory responses, effectively reducing pulmonary edema and cytokine production, thereby improving respiratory and inflammatory disease management.

WO2024232542A1PCT designated stage expired Publication Date: 2024-11-14IND FOUND OF CHONNAM NAT UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/004173
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-04-01
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for acute lung injury and acute respiratory distress syndrome are inadequate in effectively managing inflammation and lung dysfunction, leading to high morbidity and mortality, and existing probiotics show variable results in preventing inflammatory diseases.

Method used

A composition containing the Lactobacillus kunkei NCHBL-003 strain or its dead cells, which inhibits LPS-induced acute lung damage and suppresses inflammatory responses by reducing the production of inflammatory cytokines and chemokines, is used to treat, prevent, or improve respiratory and inflammatory diseases.

Benefits of technology

The composition effectively reduces pulmonary edema, body temperature, and inflammatory cytokine production in animal models, demonstrating its ability to treat and prevent respiratory and inflammatory diseases by suppressing acute lung damage and inflammatory responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024004173_14112024_PF_FP_ABST
    Figure KR2024004173_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition containing Lactobacillus kunkeei NCHBL-003 strain or inactivated cells thereof as an active ingredient for the treatment, prevention, or alleviation of respiratory or inflammatory diseases. The composition effectively suppresses LPS-induced acute lung injury and exhibits anti-inflammatory effects, and thus can be effectively used for treating, preventing, or alleviating respiratory or inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for treating, preventing or improving respiratory diseases or inflammatory diseases comprising Lactobacillus kunkai NCHBL-003 strain or killed cells thereof as an active ingredient

[0001] This invention was made under the support of the Ministry of Science and ICT (MSIT) under the research project number 1711154062, the research management specialized institution of the project is the National Research Foundation of Korea, the research project name is "Individual Basic Research (MSIT)", the research project name is "Study on the disease control mechanism of probiotics through regulation of node-like receptor signaling", the main institution is Chonnam National University Industry-Academic Cooperation Foundation, and the research period is 2022.03.01 ~ 2027.02.28.

[0002] This patent application claims priority to Republic of Korea Patent Application No. 10-2023-0061143, filed with the Korean Intellectual Property Office on May 11, 2023, the disclosure of which is incorporated herein by reference.

[0003] The present invention relates to a composition for treating, preventing or improving respiratory diseases or inflammatory diseases, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient, and more particularly, to a technology for using Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof for the treatment, prevention or improvement of respiratory diseases or inflammatory diseases caused by lung function abnormalities such as acute lung injury and acute respiratory distress syndrome.

[0004] Acute lung injury (ALI) is a syndrome characterized by physiological, clinical, and radiological abnormalities due to inflammation and increased permeability of the lungs, resulting from various causes. Acute respiratory distress syndrome (ARDS) is a clinical and pathophysiological syndrome caused by acute lung injury, characterized by severe dyspnea, hypoxemia, extensive bilateral pulmonary infiltrates, and markedly reduced lung compliance.

[0005] The causes of the disease are diverse, including infection by pathogens, trauma, and genetic predisposition, and it is considered a very important disease clinically due to its high morbidity and mortality rates in both adults and children.

[0006] Acute lung injury and acute respiratory distress syndrome, whether originating in the alveoli or pulmonary vasculature, ultimately lead to a severe pulmonary inflammatory response, manifesting in a variety of pathophysiological manifestations. Pathological findings of acute lung injury primarily reveal the inflammatory response, which fills the alveoli with inflammatory cells and proteins, forming hyaline membranes, and infiltrating the pulmonary interstitium. Various cytokines play a role in this process, and abnormalities in blood coagulation are often observed.

[0007] Meanwhile, microorganisms of the genus Lactobacillus are lactic acid bacteria that undergo homotypic or heterotypic fermentation, and are commonly found in the fermentation process of dairy products and vegetables, and are mostly classified as beneficial bacteria. Recently, many studies have reported that administering probiotics such as Lactobacillus or Bifidobacterium, which are beneficial intestinal bacteria, has an effect in preventing respiratory diseases. In addition, many studies have reported results showing that beneficial intestinal bacteria have a protective effect against inflammatory diseases. However, the results of the protective effect on inflammatory diseases vary depending on the type of lactic acid bacteria, and therefore additional research in this regard is necessary.

[0008] Accordingly, the inventors of the present invention confirmed that Lactobacillus kunkeei NCHBL-003 derived from honeybees has excellent acute lung injury inhibition and anti-inflammatory effects.

[0009] Accordingly, the purpose of the present invention is to provide a Lactobacillus kunkeei NCHBL-003 strain deposited under the accession number KCTC 14908BP.

[0010] Another object of the present invention is to provide a pharmaceutical composition for treating or preventing respiratory diseases or inflammatory diseases due to pulmonary dysfunction, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

[0011] Another object of the present invention is to provide a health functional food composition for improving respiratory diseases or inflammatory diseases due to pulmonary dysfunction, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

[0012] Another object of the present invention relates to the use of Lactobacillus kunkeei NCHBL-003 strain or its killed cells for the treatment, prevention or improvement of respiratory diseases or inflammatory diseases caused by lung function abnormalities.

[0013] The present invention relates to a composition for treating, preventing or improving respiratory diseases or inflammatory diseases due to lung function abnormalities, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient. The composition according to the present invention not only suppresses acute lung injury induced by LPS, but also exhibits an effect of suppressing macrophage inflammatory response induced by LPS.

[0014] The present inventors confirmed that live or killed Lactobacillus kunkeei derived from honeybees improved pulmonary edema and suppressed inflammation in alveolar lavage fluid in a mouse model of LPS-induced acute lung injury, and suppressed inflammatory responses in LPS-induced macrophages.

[0015]

[0016] Hereinafter, the present invention will be described in more detail.

[0017]

[0018] One aspect of the present invention is the Lactobacillus kunkeei NCHBL-003 strain deposited under accession number KCTC 14908BP.

[0019]

[0020] Another aspect of the present invention is a pharmaceutical composition for treating or preventing respiratory diseases due to abnormal lung function, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

[0021] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may include the 16S rRNA base sequence described in sequence number 1.

[0022] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may be deposited under the accession number KCTC 14908BP.

[0023] In the present invention, the dead cells may be obtained by killing a strain with heat or radiation, and for example, may be obtained by killing by heat treatment, but is not limited thereto. A strain killed by heat treatment can be generally understood to have only the characteristics of the strain wall.

[0024] In the present invention, the respiratory disease due to the abnormality in lung function may be at least one selected from the group consisting of acute lung injury and acute respiratory distress syndrome, but is not limited thereto.

[0025] In the present invention, the above-mentioned lung function abnormality may be caused by lipopolysaccharide (LPS), but is not limited thereto.

[0026] In the present invention, the pharmaceutical composition may inhibit the production of one or more substances selected from the group consisting of interleukin-6 (IL-6), interleukin-1 beta (IL-1β), interferon-gamma (IFN-γ), TNF-alpha (TNF-α), CXCL1, CXCL16, MCP-1, and TARC, but is not limited thereto.

[0027] The pharmaceutical composition of the present invention can be used as a pharmaceutical composition comprising a pharmaceutically effective amount of Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof and / or a pharmaceutically acceptable carrier.

[0028] The term “pharmaceutically effective amount” as used herein means an amount sufficient to achieve the efficacy or activity of the Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof described above.

[0029] Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.

[0030] The pharmaceutical composition according to the present invention can be administered to mammals, including humans, via various routes. Any commonly used route of administration may be used, including oral, transdermal, intravenous, intramuscular, and subcutaneous administration, with oral administration being preferred.

[0031] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a generally skilled physician can easily determine and prescribe a dosage effective for the desired treatment or prevention.

[0032] The pharmaceutical composition of the present invention can be manufactured in a unit dosage form or can be manufactured by inserting it into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablets, capsules or gel (e.g., hydrogel), and may additionally include a dispersing agent or stabilizer.

[0033]

[0034] Another aspect of the present invention is a pharmaceutical composition for treating or preventing an inflammatory disease, comprising Lactobacillus kunkeei NCHBL-003 strain or a killed cell thereof as an active ingredient.

[0035] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may include the 16S rRNA base sequence described in sequence number 1.

[0036] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may be deposited under the accession number KCTC 14908BP.

[0037] In the present invention, the inflammatory disease may be at least one selected from the group consisting of rheumatoid arthritis, osteoarthritis, degenerative arthritis, polyarthritis, acute inflammation, allergic inflammation, and skin disease, but is not limited thereto.

[0038] In the present invention, the inflammatory disease may be caused by lipopolysaccharide (LPS), but is not limited thereto.

[0039] In the present invention, the pharmaceutical composition may suppress the production of one or more substances selected from the group consisting of interleukin-6 (IL-6) and TNF-alpha (TNF-α), but is not limited thereto.

[0040]

[0041] Another aspect of the present invention is a health functional food composition for improving respiratory diseases due to pulmonary dysfunction, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

[0042] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may include the 16S rRNA base sequence described in sequence number 1.

[0043] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may be deposited under the accession number KCTC 14908BP.

[0044] When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. Generally, when manufacturing a food or beverage, the food composition of the present invention may be added in an amount of 15% by weight or less, preferably 10% by weight or less, relative to the raw materials.

[0045] There are no specific restrictions on the types of the above foods. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and all foods in the conventional sense are included.

[0046] The above beverage may contain various flavoring agents or natural carbohydrates as additional ingredients. The above-mentioned natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, or synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates may be appropriately determined by those skilled in the art.

[0047] In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the health functional food composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients may be used independently or in combination. The proportions of these additives may also be appropriately selected by those skilled in the art.

[0048]

[0049] Another aspect of the present invention is a health functional food composition for improving inflammatory diseases, comprising Lactobacillus kunkeei NCHBL-003 strain or a killed cell thereof as an active ingredient.

[0050] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may include the 16S rRNA base sequence described in sequence number 1.

[0051] In the present invention, the Lactobacillus kunkeei NCHBL-003 strain may be deposited under the accession number KCTC 14908BP.

[0052] The present invention relates to a composition for treating, preventing or improving respiratory diseases or inflammatory diseases due to pulmonary dysfunction, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient. The composition exhibits an effect of inhibiting acute lung injury induced by LPS and an effect of inhibiting macrophage inflammatory response, and thus can be effectively used for treating, preventing or improving respiratory diseases or inflammatory diseases due to pulmonary dysfunction.

[0053] Figure 1 is a graph showing the body temperature increase suppression effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells in an LPS-induced acute lung injury animal model.

[0054] Figure 2 is a graph showing the pulmonary edema suppression effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells in an LPS-induced acute lung injury animal model.

[0055] Figure 3a is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of inflammatory cytokine IL-6 in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0056] Figure 3b is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of inflammatory cytokine TNF-α in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0057] Figure 3c is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of inflammatory cytokine IL-1β in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0058] Figure 3d is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of inflammatory cytokine IFN-γ in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0059] Figure 3e is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of chemokine CXCL1 in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0060] Figure 3f is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of chemokine CXCL16 in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0061] Figure 3g is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of chemokine MCP-1 in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0062] Figure 3h is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on the production of chemokine TARC in bronchoalveolar lavage fluid in an animal model of LPS-induced acute lung injury.

[0063] Figure 4a is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 dead cells on the production of inflammatory cytokine IL-6 in mouse-derived macrophages stimulated with LPS.

[0064] Figure 4b is a graph showing the inhibitory effect of Lactobacillus kunkeei NCHBL-003 dead cells on the production of inflammatory cytokine TNF-α in mouse-derived macrophages stimulated with LPS.

[0065] A pharmaceutical composition for treating or preventing respiratory diseases due to lung function abnormalities, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

[0066] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are intended only to illustrate the present invention, and the scope of the present invention is not limited by these examples.

[0067]

[0068] Example 1: Isolation and identification of Lactobacillus kunkeei NCHBL-003 strain

[0069] To isolate lactic acid bacteria from the gut microbiota of honeybees, the target insects were first collected in the Gwangju area in early June, placed in sterilized collection containers, and refrigerated for 10 minutes for each individual. The gastrointestinal tracts were aseptically removed using microsurgical instruments on a green bench. The honeybee gut microbiota was obtained by suspending the extracted gastrointestinal contents in 10 ml of sterile Tween 80-added 0.1% peptone physiological saline (0.9% w / v NaCl, 0.1% w / v Tween 80, 0.1% w / v peptone).

[0070] Lactic acid bacteria were suspended in 500 ul of the comminuted intestines in a liquid medium (Difco TM After serially diluting appropriately using Lactobacilli MRS Broth, BD, USA), the solid medium (BBL) was plated using a platinum plate. TM Spread on LBS Agar (BD, USA) and BD GasPak TMEZdp was added and cultured at 37℃ until bacterial colonies were confirmed. Bacterial colonies confirmed on LBS solid medium were identified as Lactobacillus based on the Gram-positive result of Gram stain and the catalase-negative reaction confirmed when mixed with 3% hydrogen peroxide. The isolated field isolate Lactobacillus was stored at -20℃ in MRS medium containing 15% glycerol and used in the following experiments.

[0071] Phylogenetic identification of Lactobacillus kunkeei NCHBL-003 among the isolated strains was performed through base sequence analysis of the 16S rRNA gene, and the 16S rRNA gene was compared with that of other Lactobacillus strains based on the similarity of the primary and secondary structures of the 16S rRNA gene using the PHYDIT program.

[0072] Sequence number name Sequence 1 Lactobacillus Kunkeei NCHBL-00316SrRNATGCAGTCGAACGAGCTCTCCCAAATTGATTTTATGCTTGCATAAATGATTTTTGGATTCGGAGCGAGTGGCGAACTGGTGAGTAACACGTGGGTAACCTGCCCCGAAGCGGGGGATAACATTTGGAAACAAGTGCTAATACCGCATAATTAGTTGGAACCGCATGGTTCCAACTTGAAAGATGGCTCTGCTATCACTTTGGGATGGACCCGCGCCGTATTAGTTAGTTGGTGAGATAAAAGCCCACCAAGACGATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGAGCAACGCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAACTCTGTTGTTAAAGAAGAACAAGTGTTAGAGTAACTGTTAACACTTTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTGTAAGTCTGCTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCAGTGGAAACTACAAAACTTGAGTACAGAAGAGGAAAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTTTCTGGTCTGTTACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATACTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGTATTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGTGGTGGAGCATGTGGTTTAATTCGATGCTACGCGAAGAACCTTACCAGCTCTTGACATCTTTCTGCCAACC

[0073]

[0074] Example 2: Experiment on the inhibitory effect of Lactobacillus kunkeei NCHBL-003 strain or its killed cells on LPS-induced acute lung injury.

[0075] 2-1. Selection of animal models for acute lung injury

[0076] As an animal model of acute respiratory distress syndrome (ARDS), a representative symptom of acute lung injury, lipopolysaccharides (LPS), a component of the cell wall of Gram-negative bacteria, are mainly administered into the bronchial tubes.

[0077]

[0078] 2-2. Laboratory animals

[0079] In this experiment, 7-week-old male BALB / c mice were used and housed in an environment set at 22 ± 2°C, 50 ± 10% relative humidity, and a 12-h light / dark cycle. After obtaining the animals, they were housed for approximately 1 week to acclimate to the environment before being used in the experiment.

[0080]

[0081] 2-3. Creation of an animal model of acute lung injury

[0082] After anesthesia with intraperitoneal injection of zoretil and lumpun, lipopolysaccharides (LPS) were administered intranasally. After measuring body temperature at 18 hours after inflammation, necropsy was performed to obtain pulmonary edema and bronchoalveolar lavage fluid.

[0083] To confirm the inhibitory effect of Lactobacillus kunkeei NCHBL-003 on acute lung injury, 1*10 Lactobacillus kunkeei NCHBL-003 strain or its killed cells were administered 2 days before lipopolysaccharides (LPS) administration. 9 The experimental group was administered orally three times at a CFU concentration. Dexamethasone was used as a drug control. The experimental group settings are shown in Table 2 below.

[0084] Group Administration substance (number of animals per group, administration method) 1 Control PBS (n=5, PO) 2 LPS PBS (n=5, PO) 3 LPS Examamethasone (n=5, PO) 4 LPS Lactobacillus kunkai NCHBL-003 1*10 9 CFU / mouse (n=5, PO) 5 LPS 1*10 of killed Lactobacillus kunkai NCHBL-003 9 CFU / mouse (n=5, PO)

[0085]

[0086] 2-4. Temperature measurement

[0087] To measure the fever generated in the LPS-induced acute lung injury model before sacrifice, the body temperatures of all experimental animals were measured and are shown in Figure 1 and Table 3.

[0088] As can be seen in Figure 1 and Table 3, body temperature increased in the LPS-induced acute lung injury model (Group 2, LPS) compared to the control group (Group 1, control).

[0089] Meanwhile, Lactobacillus kunkeei NCHBL-003 strain (Group 4) or its dead cells (Group 5) were added at 1*10 9 In the group administered orally at a CFU concentration, body temperature decreased.

[0090] Group Administration substance Body temperature (mean value, unit: ℃) 1 Control PBS 35.82 LPS BBS 37.73 LPS Examamethasone 36.74 LPS NCHBL-00336.95 LPS Sterilized NCHBL-00336.4

[0091]

[0092] 2-5. Lung weight measurement

[0093] To determine the degree of pulmonary edema, the lungs of all experimental animals were removed on the day of sacrifice, weighed (wet weight), dried for 48 hours, and then measured for dry weight, which are shown in Fig. 2 and Table 4.

[0094] As can be seen in Figure 2 and Table 4, pulmonary edema increased in the LPS-induced acute lung injury model (Group 2, LPS) compared to the control group (Group 1, control).

[0095] Meanwhile, Lactobacillus kunkeei NCHBL-003 strain (Group 4) or its dead cells (Group 5) were added at 1*10 9 In the group administered orally at a CFU concentration, pulmonary edema was reduced.

[0096] Group Weight of administered substance (mean, unit: g) 1 Control PBS 2.67 2 LPS BS 4.80 3 LPS dexamethasone 3.14 4 LPS SNCHBL-003 4.00 5 LPS sterilized NCHBL-003 2.86

[0097]

[0098] 2-6. Collection of bronchoalveolar lavage fluid

[0099] On the day of sacrifice, mice were anesthetized with intraperitoneal injections of zoretil and rumpun. The neck and chest were opened to expose the lungs and trachea. After securing the upper part of the trachea with intubation, PBS was injected, and the chest was massaged for 30 seconds. Bronchoalveolar lavage fluid (BALF) was collected from the lungs.

[0100] The production of inflammatory cytokines IL-6, TNF-α, IL-1β, IFN-γ and chemokines CXCL1, CXCL16, MCP-1, and TARC in bronchoalveolar lavage fluid was measured using a commercial ELISA kit, and is shown in Figures 3a to 3h and Table 5.

[0101] As can be seen in Figures 3a to 3h and Table 5, the expression of inflammatory cytokines and chemokines was significantly increased in the LPS-induced acute lung injury model (G2, LPS) compared to the control group (G1, control).

[0102] Meanwhile, Lactobacillus kunkeei NCHBL-003 strain (Group 4) or its dead cells (Group 5) were added at 1*10 9 In the group administered orally at CFU concentrations, the production of inflammatory cytokines IL-6, TNF-α, and IL-1β was significantly reduced (Figures 3a to 3c).

[0103] On the other hand, IFN-γ production showed a significant decrease in the group orally administered killed Lactobacillus kunkeei NCHBL-003 (Group 5) (Fig. 3d).

[0104] Additionally, 1*10 of Lactobacillus kunkeei NCHBL-003 strain (Group 4) or its dead cells (Group 5) 9 In the group administered orally at CFU concentrations, the production of chemokines CXCL1, CXCL16, MCP-1, and TARC was significantly reduced (Figures 3e to 3h).

[0105] From this, it was confirmed that Lactobacillus kunkeei NCHBL-003 strain or its killed strain was effective in treating, preventing or improving respiratory diseases due to lung function abnormalities by suppressing pulmonary edema and inflammatory responses in an animal model of acute lung injury induced by LPS.

[0106] LPS-++++Dexamethasone--+--NCHBL-003---+-Killed NCHBL-003---+IL-6 (pg / ml)169913686.52976.574197014TNF-α (pg / ml)13927994716041249IL-1β (pg / ml)272.31510.7636.5919.8934.8IFN-γ (pg / ml)275.5321.8179.3243231.8CXCL1 (pg / ml)69730.7289.6408.4435.1CXCL16 (pg / ml)67.5598.8288.8455.6432.5MCP-1 (pg / ml)46738329517520TARC (pg / ml)30.7584.8309.8443.2426.5

[0107]

[0108] Example 3: Experiment on the inhibitory effect of LPS-induced macrophage inflammatory response using killed cells of Lactobacillus kunkeei NCHBL-003 strain.

[0109] 3-1. Isolation and culture of bone marrow-derived macrophages (BMDMs)

[0110] Bone marrow was isolated from the femurs and tibias of 8- to 12-week-old C57BL / 6 mice and cultured in IMDM medium containing 30% L929 cell culture medium, 10% fetal bovine serum (FBS), 1% penicillin / streptomycin (P / S), 1% non-essential amino acids, and 1% sodium pyruvate for 6 days in an incubator at 37°C and 5% CO2. An additional medium was supplied on the third day of culture.

[0111]

[0112] 3-2. Measurement of inflammatory cytokine production

[0113] 2x10 mouse macrophages 5 / well in a 48-well plate, the cells were cultured in IMDM medium supplemented with 10% FBS and 1% PS for 6 days at 37°C and 5% CO2 in an incubator. After 24 h, the cells were pretreated with killed Lactobacillus kunkeei NCHBL-003 at concentrations of 50, 100, 200, and 400 μg / ml for 2 h. Afterwards, LPS was treated at a concentration of 100 ng / ml and cultured for 24 h in an incubator at 37°C and 5% CO2.

[0114] After 24 hours, the cell supernatant was collected, and the production of inflammatory cytokines IL-6 and TNF-α was measured using a commercial ELISA kit, and the quantification was shown in Figures 4a to 4b and Table 6.

[0115] As can be seen in Figures 4a to 4b and Table 6, the production of inflammatory cytokines IL-6 and TNF-α increased in mouse macrophages due to LPS stimulation.

[0116] Meanwhile, the production of IL-6 and TNF-α by the sterilized Lactobacillus kunkeei NCHBL-003 strain was significantly reduced in a concentration-dependent manner (Figs. 4a to 4b).

[0117] From this, it was confirmed that the Lactobacillus kunkeei NCHBL-003 strain is effective in treating, preventing, or improving inflammatory diseases by suppressing the inflammatory response in LPS-induced mouse macrophages.

[0118] LPS-+++++Pulmonated NCHBL-003(㎍ / ml)--50100200400IL-6 (pg / ml)0490.1470.5210.800TNF-α (pg / ml)04125.12345.51808.2819.470.4

[0119]

[0120] [Accession number]

[0121] Name of depositor: Korea Research Institute of Bioscience and Biotechnology

[0122] Accession number: KCTC 14908BP

[0123] Date of acceptance: 20220317

[0124] The present invention relates to a composition for treating, preventing or improving respiratory diseases or inflammatory diseases, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

[0125]

[0126] [Deposit Certificate]

[0127] [Correction pursuant to Rule 91, May 8, 2024]

Claims

1. Lactobacillus kunkeei NCHBL-003 strain deposited under accession number KCTC 14908BP.

2. A pharmaceutical composition for treating or preventing respiratory diseases due to lung function abnormalities, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

3. A pharmaceutical composition according to claim 2, wherein the Lactobacillus kunkeei NCHBL-003 strain comprises the 16S rRNA base sequence described in sequence number 1.

4. A pharmaceutical composition according to claim 2, wherein the Lactobacillus kunkeei NCHBL-003 strain is deposited under the accession number KCTC 14908BP.

5. A pharmaceutical composition according to any one of claims 2 to 4, wherein the respiratory disease due to lung function abnormality is at least one selected from the group consisting of acute lung injury and acute respiratory distress syndrome.

6. A pharmaceutical composition according to any one of claims 2 to 4, wherein the lung function abnormality is caused by lipopolysaccharide (LPS).

7. A pharmaceutical composition according to any one of claims 2 to 4, wherein the pharmaceutical composition inhibits the production of at least one substance selected from the group consisting of interleukin-6 (IL-6), interleukin-1 beta (IL-1β), interferon-gamma (IFN-γ), TNF-alpha (TNF-α), CXCL1, CXCL16, MCP-1, and TARC.

8. A pharmaceutical composition for treating or preventing inflammatory diseases, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

9. A pharmaceutical composition according to claim 8, wherein the Lactobacillus kunkeei NCHBL-003 strain comprises the 16S rRNA base sequence described in sequence number 1.

10. A pharmaceutical composition according to claim 8, wherein the Lactobacillus kunkeei NCHBL-003 strain is deposited under the accession number KCTC 14908BP.

11. A pharmaceutical composition according to any one of claims 8 to 10, wherein the inflammatory disease is at least one selected from the group consisting of rheumatoid arthritis, osteoarthritis, degenerative arthritis, polyarthritis, acute inflammation, allergic inflammation, and skin disease.

12. A pharmaceutical composition according to any one of claims 8 to 10, wherein the inflammatory disease is caused by lipopolysaccharide (LPS).

13. A pharmaceutical composition according to any one of claims 8 to 10, wherein the pharmaceutical composition inhibits the production of at least one substance selected from the group consisting of interleukin-6 (IL-6) and TNF-alpha (TNF-α).

14. A health functional food composition for improving respiratory diseases due to pulmonary dysfunction, comprising Lactobacillus kunkeei NCHBL-003 strain or killed cells thereof as an active ingredient.

15. A health functional food composition according to claim 14, wherein the Lactobacillus kunkeei NCHBL-003 strain comprises the 16S rRNA base sequence described in sequence number 1.

16. A health functional food composition according to claim 14, wherein the Lactobacillus kunkeei NCHBL-003 strain is deposited under the accession number KCTC 14908BP.

17. A health functional food composition for improving inflammatory diseases, comprising Lactobacillus kunkeei NCHBL-003 strain or a killed cell thereof as an active ingredient.

18. A health functional food composition according to claim 17, wherein the Lactobacillus kunkeei NCHBL-003 strain comprises the 16S rRNA base sequence described in sequence number 1.

19. A health functional food composition according to claim 17, wherein the Lactobacillus kunkeei NCHBL-003 strain is deposited under the accession number KCTC 14908BP.

Citation Information

Patent Citations

  • Lactic acid bacterium having IgA production promoting activity, and use thereof

    US10570366B2

  • Inhaled respiratory probiotics for lung diseases of infancy, childhood and adulthood

    US20210361726A1

  • Composition for preventing, treating, or improving metabolic diseases, comprising lactobacillus kunkeei nchbl-003 strain or culture medium thereof

    WO2023229282A1